In the past two years, the most discussed in the industry is the recombinant collagen track.
From Shiseido and LVMH successively betting on China's recombinant collagen companies, to L'Oreal's first product to add "recombinant collagen", all prove that this raw material originated in China is indeed "popular".
Relevant data show that in 2022, the scale of China's recombinant collagen market will reach 18.5 billion yuan, accounting for 46.6% of the collagen market, a year-on-year increase of 71.3%, and the market size is expected to reach 108.3 billion yuan by 2027.
Today, this 100 billion market welcomes "high-end players".
On December 15, at the 2023 Recombinant Collagen Technology Summit and Freda Collagen Achievement Release, Freda Biological Co., Ltd., which created a precedent for hyaluronic acid skin care in China, disclosed its scientific research achievements in the field of collagen for the first time, and announced in a high-profile manner: the launch of the first medical beauty brand KeyC, focusing on the layout of the recombinant collagen industry chain.
This means that on the occasion of the 25th anniversary of Freda Biological Co., Ltd., this "old gun" in the field of hyaluronic acid is standing at a new starting point, opening up a new situation and drawing a second growth curve.
Recombinant collagen will usher in an explosive period
The term "collagen" is not unfamiliar, and it is not difficult to find that it has been studied for more than a hundred years when you look through its historical archives.
Zhang Guifeng, a researcher at the Institute of Process Engineering of the Chinese Academy of Sciences, gave a comprehensive introduction to the research history, structure and function of collagen, the relationship between collagen and diseases, and the future development direction of collagen.
Zhang Guifeng, a researcher at the Institute of Process Engineering, Chinese Academy of Sciences
He pointed out that collagen, as the main component of the extracellular matrix, is almost ubiquitous in the human body, and collagen interacts with cells to affect cell migration, proliferation, differentiation and adhesion, and its type, proportion, synthesis and metabolic changes will have a huge impact on the human body.
In recent years, the popular "recombinant collagen" is the collagen prepared by DNA recombination and synthetic biology technology, and its most important feature is that it is the same or similar to the amino acid sequence of human collagen, so it has the characteristics of good homology and high safety, and is widely used in dressings, regenerative medicine, beauty and makeup.
For example, "type XVII collagen is closely related to the aging of skin tissue cells, and is involved in the regulation of epidermal stem cells, the regulation of hair growth cycle, and the regulation of genes related to the basement membrane barrier, and has broad application prospects." Professor Liu Wei, consultant dermatologist and professor of dermatology of the Chinese Medical Doctor Association, said.
Professor Liu Wei, consultant dermatologist and professor of dermatology of the Chinese Medical Doctor Association
Professor Yao Min, deputy dean of the School of Clinical Medicine of the Ninth Hospital of Shanghai Jiao Tong University School of Medicine and the leader of the optoelectronic technology discipline of the Ninth Hospital of Plastic and Rehabilitation Surgery, said that collagen can be used externally in the form of skin care products or wound dressings in medical cosmetology, and can be used internally through oral administration or injection to achieve cosmetic effects, but any clinical application has potential risks and requires cautious and professional guidance.
Professor Yao Min, Vice Dean of the School of Clinical Medicine of the Ninth Hospital of Shanghai Jiao Tong University School of Medicine and the leader of the optoelectronic technology discipline of the Ninth Hospital of Plastic and Plastic Surgery
Regarding the current situation and development trend of recombinant collagen technology research at home and abroad, Huang Yadong, professor of the School of Life Science and Technology of Jinan University and chief scientist of Guangdong Peptide Source Technology Group Co., Ltd., pointed out: "In the field of recombinant collagen, there are still 'stuck neck' technical problems to be solved, such as difficulty in forming a triple helix structure, low expression level, and low purification efficiency, and continuous technical cultivation is still needed. ”
Huang Yadong, professor of the School of Life Science and Technology of Jinan University and chief scientist of Guangdong Peptide Source Technology Group Co., Ltd
It is understood that at present, there are not many enterprises in China that have mastered the "recombinant collagen" technology, and the recombinant collagen market pattern is relatively scattered, and the industry concentration is low, resulting in the existing situation because the biosynthesis technology has certain technical barriers, and the capital investment is huge, and at the same time, there is no overseas experience to refer to.
"In the future, as recombinant collagen is supported by more scientific experiments and clinical data, the market application in the field of skin care and medical aesthetics is about to usher in an explosive period, and at the same time, with the continuous increase in the market penetration rate of end products, recombinant collagen in mainland China will also enter a standardized and orderly development upward channel. Yang Suzhen, deputy general manager of Freda Biotechnology Co., Ltd., said to "Cosmetics Observation".
Launched the first recombinant collagen brand
The territory of "double beauty" has appeared
Based on the insight into the market trend and the continuous innovation ability, Freda Biological Co., Ltd. has formed a complete industrial chain from the development of raw materials and finished products to channel operation and brand promotion since the layout of the recombinant collagen industry, and has become one of the few enterprises that have mastered the technology of "recombinant collagen".
Gao Chunming, general manager of Freda Biological Co., Ltd
At the meeting, Gao Chunming, general manager of Freda Biological Co., Ltd., officially announced two news related to the industry at the meeting: first, the recombinant collagen was officially put into production, and second, the medical beauty brand Kemi was officially released.
He said excitedly: "Today, we will usher in a new beginning. ”
Specifically, in the field of recombinant collagen, Freda Biotech has been deeply cultivated for many years and has achieved fruitful results.
According to Liu Fei, director of the basic research department of Shandong Freda Biological Co., Ltd., Freda used synthetic biology technology to scientifically select the highly bioactive site enrichment fragments in the amino acid sequence of human type III collagen, and obtained high-activity and high-purity recombinant humanized type III collagen through efficient expression and multi-stage extraction and purification of Escherichia coli.
In response to the market controversy over whether collagen can be absorbed through the skin and whether it can play a role on the skin, Liu Fei responded that Freda highly simulated the osmotic absorption and metabolism process of the skin in vitro through the isolated skin model, and found that recombinant humanized type III collagen has significant effects of epidermal repair, basement membrane remodeling, and dermal regeneration, so as to achieve three-dimensional anti-aging repair, layer by layer to block aging damage, and can effectively fight oxidative free radicals, anti-carbonylation, Inhibits inflammation and hits the root cause of skin aging and damage.
Liu Fei, Director of the Basic Research Department of Shandong Freda Biological Co., Ltd
"The combination of recombinant humanized type III collagen and hyaluronic acid has a synergistic effect in promoting the expression of keratinocyte skeletal proteins and proteins related to the formation of keratinized envelopes, promoting the expression of tight junction proteins, collagen and elastin, and reducing DNA damage, which can achieve a breakthrough of "1+1>2" and open up a broader development space for the development of collagen. Liu Fei said.
On the brand side, as the "representative work" of Freda's layout of recombinant collagen, Kemi starts from the root of anti-aging and repair, and provides consumers with a scientific and professional "perioperative" care plan for light medical beauty by creating a recombinant collagen combined with hyaluronic acid synergistic formula.
Liu Fei said that Kemi's recombinant collagen anti-aging essence has achieved remarkable results in increasing skin hydration, improving skin redness, enhancing barrier function, reducing wrinkles and increasing skin elasticity.
It can be seen that Freda Biotech Co., Ltd. is drawing a second growth curve through a comprehensive layout of recombinant collagen, which not only completes the territory explored in the field of beauty industry, but also upgrades from a single beauty main business to a new ecology of "raw beauty + medical beauty".
Freda rushed to 10 billion
"From the leader of hyaluronic acid to the game-changer of recombinant collagen, we should be thankful that we are living in a great era. Fortunately, we are standing on the shoulders of the giants. Gao Chunming looked back on the past 25 years and was quite emotional.
He pointed out that from its birth to the present, Freda Biological Co., Ltd. has gone through three stages: exploration period (1998-2002), entrepreneurial period (2003-2010), and development period (2011-present). "In the development period, Freda Biological Co., Ltd. adopted a three-step strategy to realize the development of small steps (channel strategy stage) - big stride fast run (multi-brand development strategy) - leap run (industrial ecological strategy stage). ”
Today, Freda Biotech has grown from a marginal enterprise of the group to a well-deserved "Golden Bull" enterprise, and has created a brilliant report card.
According to financial data, in 2022, the company's sales revenue will exceed 1.8 billion yuan, with a compound growth rate of 82.43% in the past three years, and the net profit will be 188.641 million yuan, with a compound growth rate of 79.77% in the past three years. In addition, the average proportion of R&D investment in sales revenue in the past four years is 3.85%, with a cumulative investment of 154 million yuan.
It can be said that with the official production of recombinant collagen and the official release of the medical beauty brand Kemi, Freda Biotech has completed a new iteration and upgrade.
On the brand side, Freda has upgraded from the "4+N" brand strategy to the "5+N" brand development strategy. Specifically, 5 represents the five main brands of Yilian, Dr. Aier, Iparkhan, Shanyan and Kemi, focusing on the layout of hyaluronic acid +, microecological skin care, recombinant collagen, precision skin care, and essential oil skin care 5 tracks, while N represents brands such as Quanrun, Beirun and UMT.
It is worth mentioning that Yilian and Dr. Aier have grown into super brands with over 1 billion yuan.
In terms of industrial ecology, Freda Biotech has also upgraded from a single beauty main business to a new ecology of "raw beauty + medical beauty". At present, the company not only has the industry's first transparent factory and collagen smart factory, but also has an output value of 4 billion yuan.
On the R&D side, Freda Biotech Co., Ltd. has also built a 5+N technology matrix relying on the R&D Innovation Center of the headquarters and the Shanghai Science and Technology Innovation Center, and has more than 120 valid patents, which has strong competitiveness.
If the development path of Freda Biological Co., Ltd. is summarized, Gao Chunming boils it down to a formula: insight into the market + continuous innovation + strong organizational power + ecological power of the whole industry = the long-term vitality of Freda Bio Co., Ltd.
As for the future, Gao Chunming has more expectations: "In the next 5-8 years, Freda Biological Co., Ltd. will build two 2 billion brands and multiple 1 billion brands through the 1234 high-quality development strategy, and become the leader of the intelligent connection of the same business format of cosmetics and drugs." ”
The future is here. On the journey to the sea of stars, Freda Biological Co., Ltd. is "double beauty gathering" and sailing to the light.
【Copyright Notice】This article is the author's independent point of view and does not represent the position of Pinguan.com/Pinguan APP. If you need to reprint, please contact the original author. If you need to authorize other content on this site, please contact [email protected].